Skip to main navigation Skip to search Skip to main content

Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing

  • Wook Oh Sang
  • , Dae Moon Jung
  • , Yeol Park Sang
  • , Jae Jang Heuk
  • , Hoon Kim Jae
  • , Bong Nahm Ki
  • , Yul Choi Eui*
  • *Corresponding author for this work
  • BodiTech Med, Inc
  • Seoul National University
  • Hanyang University
  • Hallym University

Research output: Contribution to journalJournal articlepeer-review

Abstract

Background: C-reactive protein (CRP) is one of acute phase respondents that has been used to monitor infection and inflammation episodes. Recent studies have shown that high-sensitivity C-reactive protein (hs-CRP) is a potential risk predictor for future atherosclerosis and cardiovascular diseases (CVD). Methods: We previously developed a fluorescence-based immunochromatographic method for measuring hs-CRP concentrations (i-CHROMA™ hs-CRP assay) in blood. Whole blood was mixed with detector buffer, and then loaded onto a test cartridge. After 10 min of incubation, the test cartridge was inserted and scanned for acquisition of fluorescence intensity in a laser fluorescence reader (i-CHROMA™ reader). The fluorescence intensity was microprocessed and converted into the concentration of CRP in blood. The test result of 150 samples by the i-CHROMA™ hs-CRP assay method was compared and evaluated with those by TBA 200FR turbidimetry and BN II nephelometry method. The Deming regression and the Bland-Altman difference plot analysis were used for comparison of hs-CRP test result. Results: The i-CHROMA™ hs-CRP assay system exhibited a good linearity with in the whole measuring range (R = 0.997). The imprecision of intra- and the inter-assay CVs (coefficient of variation) of assay system were CVs< 3% and < 5% in the range of 0.5-20 mg/l, respectively. The i-CHROMA™ hs-CRP assay method correlated well with TBA 200FR turbidimetry and BN II nephelometry assay method (R = 0.988, N = 143 and R = 0.989, N = 143). Conclusion: The i-CHROMA™ hs-CRP assay system is comparable to those of other well-known fully automated hs-CRP assay and is suitable for point-of-care testing (POCT) in detection and quantification of hs-CRP.

Original languageEnglish
Pages (from-to)172-177
Number of pages6
JournalClinica Chimica Acta
Volume356
Issue number1-2
DOIs
StatePublished - 2005.06

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Anti-CRP-mAb
  • Cardiovascular diseases
  • hs-CRP
  • Immunoassay
  • POCT

Fingerprint

Dive into the research topics of 'Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing'. Together they form a unique fingerprint.

Cite this